{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:08:12Z","timestamp":1786547292339,"version":"build-2736575974"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024679","name":"ADVANZ PHARMA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Periprosthetic joint infections pose clinical and socioeconomic challenges. Gram-negative pathogens are associated with poorer outcomes compared with Gram-positive organisms. Rising antimicrobial resistance limits treatment options. The new combination of cefepime\/enmetazobactam offers a promising carbapenem-sparing therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the distribution and the time above the minimum inhibitory concentration for cefepime and the time above the threshold concentration for enmetazobactam during the first and third dosing intervals in tissues relevant to periprosthetic joint infection, following either intermittent short-term infusion or continuous infusion in a preclinical, randomized porcine model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Sixteen pigs were randomized to receive cefepime\/enmetazobactam either as a short-term infusion (2\u2005g\/0.5\u2005g over 2\u2005h) or continuous infusion (initial dosage of 1\u2005g\/0.25\u2005g administered over 15\u2005min followed by 2\u2005g\/0.5\u2005g over 7\u2005h and 45\u2005min) in three dosing intervals of 8\u2005h. Microdialysis was used to dynamically sample interstitial fluid concentrations of cefepime and enmetazobactam from cancellous bone, subcutaneous tissue and synovial fluid. Plasma samples were collected as reference. The following dosing interval targets were applied: for cefepime, 60% T\u200a&amp;gt;\u200aMIC of 8\u2005mg\/L and for enmetazobactam, 45% of T\u200a&amp;gt;\u200aCt of 2\u2005mg\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All pigs reached the predetermined targets in all investigated compartments following both administration forms. For all targets, compartments, dosing intervals and administration forms, the mean T\u200a&amp;gt;\u200aMIC for cefepime was \u226592% and mean T\u200a&amp;gt;\u200aCt for enmetazobactam was \u226599%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cefepime\/enmetazobactam demonstrated robust tissue distribution, reaching the applied pharmacokinetic\/pharmacodynamic targets in all investigated tissue compartments, regardless of the mode of administration. From a pharmacokinetic view, cefepime\/enmetazobactam may prove useful in future Gram-negative periprosthetic joint infection settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf487","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:55:22Z","timestamp":1766062522000},"source":"Crossref","is-referenced-by-count":2,"title":["Cefepime\/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7772-7230","authenticated-orcid":false,"given":"M B D","family":"Nielsen","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus N ,","place":["Denmark"]},{"name":"Department of Orthopaedic Surgery, Aarhus University Hospital , Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M K D","family":"Mikkelsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus N ,","place":["Denmark"]},{"name":"Department of Orthopaedic Surgery, Aarhus University Hospital , Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H C","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus N ,","place":["Denmark"]},{"name":"Department of Orthopaedic Surgery, Aarhus University Hospital , Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Hvistendahl","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus N ,","place":["Denmark"]},{"name":"Department of Orthopaedic Surgery, Aarhus University Hospital , Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C H","family":"L\u00fctzh\u00f8ft","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus N ,","place":["Denmark"]},{"name":"Department of Orthopaedic Surgery, Aarhus University Hospital , Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Slater","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus N ,","place":["Denmark"]},{"name":"Department of Orthopaedic Surgery, Aarhus University Hospital , Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2754-3518","authenticated-orcid":false,"given":"C","family":"Crocoll","sequence":"additional","affiliation":[{"name":"Department of Plant and Environmental Sciences, Faculty of Science, University of Copenhagen , Frederiksberg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Poborsky","sequence":"additional","affiliation":[{"name":"Department of Plant and Environmental Sciences, Faculty of Science, University of Copenhagen , Frederiksberg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N P","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus N ,","place":["Denmark"]},{"name":"Department of Infectious Diseases, Aarhus University Hospital , Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"A","family":"Soriano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic of Barcelona, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Stilling","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus N ,","place":["Denmark"]},{"name":"Department of Orthopaedic Surgery, Aarhus University Hospital , Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bue","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus N ,","place":["Denmark"]},{"name":"Department of Orthopaedic Surgery, Aarhus University Hospital , Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2026011823443296800_dkaf487-B1","volume-title":"Healthcare-associated Infections: Surgical Site Infections","author":"Prevention ECfD, Control","year":"2019"},{"key":"2026011823443296800_dkaf487-B2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-3-031-60462-1_2","volume-title":"Infections in Surgery: Prevention and Management","author":"D\u2019Ancona","year":"2025"},{"key":"2026011823443296800_dkaf487-B3","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMra040181","article-title":"Prosthetic-joint infections","volume":"351","author":"Zimmerli","year":"2004","journal-title":"N Engl J Med"},{"key":"2026011823443296800_dkaf487-B4","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.injury.2017.03.030","article-title":"Infection after fracture fixation of the tibia: analysis of healthcare utilization and related costs","volume":"48","author":"Metsemakers","year":"2017","journal-title":"Injury"},{"key":"2026011823443296800_dkaf487-B5","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.2106\/JBJS.L.00789","article-title":"Periprosthetic joint infection increases the risk of one-year mortality","volume":"95","author":"Zmistowski","year":"2013","journal-title":"J Bone Joint Surg Am"},{"key":"2026011823443296800_dkaf487-B6","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1086\/605593","article-title":"Gram-negative prosthetic joint infections: risk factors and outcome of treatment","volume":"49","author":"Hsieh","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026011823443296800_dkaf487-B7","doi-asserted-by":"publisher","first-page":"O911","DOI":"10.1111\/1469-0691.12649","article-title":"Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study","volume":"20","author":"Rodr\u00edguez-Pardo","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2026011823443296800_dkaf487-B8","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.3390\/biomedicines11112937","article-title":"Extended-spectrum \u03b2-lactamases (ESBL): challenges and opportunities","volume":"11","author":"Husna","year":"2023","journal-title":"Biomedicines"},{"key":"2026011823443296800_dkaf487-B9"},{"key":"2026011823443296800_dkaf487-B10","doi-asserted-by":"publisher","first-page":"106497","DOI":"10.1016\/j.ijantimicag.2021.106497","article-title":"Native bone and joint infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacterales: experience of a reference centre in the Greater Paris area","volume":"59","author":"Davido","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026011823443296800_dkaf487-B11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1177\/112070001002000217","article-title":"Infections after primary and revision total hip replacement caused by enterobacteria producing extended spectrum beta-lactamases (ESBL): a case series","volume":"20","author":"Haenle","year":"2010","journal-title":"Hip Int"},{"key":"2026011823443296800_dkaf487-B12","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1128\/AAC.00188-09","article-title":"Outcome of acute prosthetic joint infections due to Gram-negative bacilli treated with open debridement and retention of the prosthesis","volume":"53","author":"Mart\u00ednez-Pastor","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011823443296800_dkaf487-B13","doi-asserted-by":"publisher","first-page":"e00514-19","DOI":"10.1128\/AAC.00514-19","article-title":"In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from U.S. and European Hospitals during 2014-2015","volume":"63","author":"Morrissey","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011823443296800_dkaf487-B14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/jac\/dkaa511","article-title":"An update on cefepime and its future role in combination with novel \u03b2-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa","volume":"76","author":"Isler","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026011823443296800_dkaf487-B15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cmi.2024.09.031","article-title":"In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives","volume":"31","author":"Bonnin","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026011823443296800_dkaf487-B16","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"2026011823443296800_dkaf487-B17","doi-asserted-by":"publisher","first-page":"e00105-19","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u03b2-lactam-\u03b2-lactamase inhibitor combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011823443296800_dkaf487-B18","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1128\/AAC.00033-15","article-title":"In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae","volume":"59","author":"Crandon","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011823443296800_dkaf487-B19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/jama.2022.22873","article-title":"Cefepime\/enmetazobactam vs piperacillin\/tazobactam and complicated urinary tract infection or acute pyelonephritis-reply","volume":"329","author":"Kaye","year":"2023","journal-title":"JAMA"},{"key":"2026011823443296800_dkaf487-B20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jama.2022.15228","article-title":"Cefepime\/enmetazobactam for complicated urinary tract infections","volume":"328","author":"Advani","year":"2022","journal-title":"JAMA"},{"key":"2026011823443296800_dkaf487-B21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40265-024-02035-2","article-title":"Cefepime\/enmetazobactam: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"2026011823443296800_dkaf487-B22","doi-asserted-by":"publisher","first-page":"e00078-20","DOI":"10.1128\/AAC.00078-20","article-title":"Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model","volume":"64","author":"Bernhard","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011823443296800_dkaf487-B23","author":"Exblifep"},{"key":"2026011823443296800_dkaf487-B24","author":"Drugs@FDA"},{"key":"2026011823443296800_dkaf487-B25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/antibiotics11040486","article-title":"Antibiotic therapy for prosthetic joint infections: an overview","volume":"11","author":"Le Vavasseur","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026011823443296800_dkaf487-B26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"2026011823443296800_dkaf487-B27","author":"EUCAST"},{"key":"2026011823443296800_dkaf487-B28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1128\/AAC.01183-09","article-title":"Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa","volume":"54","author":"Crandon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011823443296800_dkaf487-B29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13054-024-04911-5","article-title":"Impact of attaining aggressive vs. conservative PK\/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis","volume":"28","author":"Gatti","year":"2024","journal-title":"Crit Care"},{"key":"2026011823443296800_dkaf487-B30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0169-409X(00)00107-1","article-title":"Methodological issues in microdialysis sampling for pharmacokinetic studies","volume":"45","author":"de Lange","year":"2000","journal-title":"Adv Drug Deliv Rev"},{"key":"2026011823443296800_dkaf487-B31","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1007\/s12035-016-9929-8","article-title":"A review on microdialysis calibration methods: the theory and current related efforts","volume":"54","author":"Kho","year":"2017","journal-title":"Mol Neurobiol"},{"key":"2026011823443296800_dkaf487-B32","doi-asserted-by":"publisher","first-page":"S539","DOI":"10.1093\/ofid\/ofz360.1341","article-title":"1477. A randomized phase 2 study of cefepime combined with the novel extended spectrum \u03b2-lactamase inhibitor enmetazobactam in hospitalized adults with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP)","volume":"6","author":"Carmeli","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026011823443296800_dkaf487-B33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1128\/AAC.03857-14","article-title":"Continuous versus short-term infusion of cefuroxime: assessment of concept based on plasma, subcutaneous tissue, and bone pharmacokinetics in an animal model","volume":"59","author":"T\u00f8ttrup","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011823443296800_dkaf487-B34","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/antibiotics11070910","article-title":"Intermittent short-term infusion vs. continuous infusion of piperacillin: steady state concentrations in porcine cervical spine tissue evaluated by microdialysis","volume":"11","author":"Petersen","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026011823443296800_dkaf487-B35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/antibiotics12030577","article-title":"Piperacillin steady state concentrations in target tissues relevant for PJI treatment\u2014a randomized porcine microdialysis study comparing continuous infusion with intermittent short-term infusion","volume":"12","author":"Rasmussen","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026011823443296800_dkaf487-B36","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.5435\/JAAOS-D-23-01203","article-title":"Microbiology, treatment, and postoperative outcomes of Gram-negative prosthetic joint infections-a systematic review of the literature","volume":"33","author":"Gonzalez","year":"2024","journal-title":"J Am Acad Orthop Surg"},{"key":"2026011823443296800_dkaf487-B37","doi-asserted-by":"publisher","first-page":"e0123224","DOI":"10.1128\/aac.01232-24","article-title":"Targeted antimicrobial regimens for Gram-negative prosthetic joint infections: a prospective multicenter study","volume":"68","author":"Hanssen","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011823443296800_dkaf487-B38","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1007\/s00402-023-05104-5","article-title":"Gram negative periprosthetic hip infection: nearly 25% same pathogen infection persistence at a mean of 2\u2005years","volume":"144","author":"Karczewski","year":"2024","journal-title":"Arch Orthop Trauma Surg"},{"key":"2026011823443296800_dkaf487-B39","doi-asserted-by":"publisher","first-page":"112837","DOI":"10.1016\/j.injury.2025.112837","article-title":"Gram-negative and Gram-positive bacteria induce different osteolysis progression profiles over time in fracture-related infections","volume":"56","author":"Peterlin","year":"2025","journal-title":"Injury"},{"key":"2026011823443296800_dkaf487-B40","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/antibiotics12030615","article-title":"Steady-state piperacillin concentrations in the proximity of an orthopedic implant: a microdialysis porcine study","volume":"12","author":"Lille\u00f8re","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026011823443296800_dkaf487-B41","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/jac\/dkab166","article-title":"Plasma and soft tissue pharmacokinetics of ceftolozane\/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study","volume":"76","author":"Al Jalali","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl B","key":"2026011823443296800_dkaf487-B42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jac\/32.suppl_B.103","article-title":"Pharmacokinetics of cefepime: a review","volume":"32","author":"Van der Auwera","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"2026011823443296800_dkaf487-B43","doi-asserted-by":"publisher","first-page":"e01468-20","DOI":"10.1128\/AAC.01468-20","article-title":"Intrapulmonary pharmacokinetics of cefepime and enmetazobactam in healthy volunteers: towards new treatments for nosocomial pneumonia","volume":"65","author":"Das","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011823443296800_dkaf487-B44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2106\/JBJS.O.00550","article-title":"Effects of implant-associated osteomyelitis on cefuroxime bone pharmacokinetics: assessment in a porcine model","volume":"98","author":"T\u00f8ttrup","year":"2016","journal-title":"J Bone Joint Surg Am"},{"key":"2026011823443296800_dkaf487-B45","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jcpa.2017.10.001","article-title":"Suppurative inflammation and local tissue destruction reduce the penetration of cefuroxime to infected bone implant cavities","volume":"157","author":"Jensen","year":"2017","journal-title":"J Comp Pathol"},{"key":"2026011823443296800_dkaf487-B46","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/jor.23776","article-title":"Single-dose bone pharmacokinetics of vancomycin in a porcine implant-associated osteomyelitis model","volume":"36","author":"Bue","year":"2018","journal-title":"J Orthop Res"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf487\/66441981\/dkaf487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf487\/66441981\/dkaf487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:44:39Z","timestamp":1768797879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf487\/8428819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf487","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkaf487"}}